39438 Investors following Cipla. Share this News with them.
0
Like this story, share it with millions of investors on M3
Cipla’s drug gets on to US anti-AIDS initiative
Cipla’s paediatric version of triple-combination AIDS drug Triomune can now be purchased by the $15-billion PEPFAR global-initiative to treat the illness. This follows the tentative approval that paediatric Triomune got earlier this week from the US regulatory authority, the Food and Drug Administration (FDA).
There is a baby and junior version of Triomune. The baby version of Triomune will be given to the PEPFAR initiative at a cost of about $4.5-5 per month. The medicine is sold in India at $7.5 (Rs 310) per month.
In India, the drug is sold in the private market, while the PEPFAR initiative involves structured-sourcing that ensures volumes. It also guarantees API (Active Pharmaceutical Ingredient) prices, Mr Lulla said, explaining the price difference.
AIDS drugs for children have been a concern, as companies had focused their energies only on adult versions of the medicine. These used to be crushed and given to children.
Paediatric Triomune can be swallowed or dissolved in water and can be given to patients weighing as little as 5 kg. It is the first fixed-dose anti-HIV product approved for children under the age of 12 years, said, US FDA's Dr Debra Birnkrant.
